This announcement is a separate document:
莱美药业:国金证券关于莱美药业2023年度内部控制评价报告的核查意见
Laimei Pharmaceuticals: Guojin Securities's inspection opinions on Laimei Pharmaceuticals' 2023 internal control evaluation report
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.